WO2016159186A1 - Composition de type gel pour application externe - Google Patents
Composition de type gel pour application externe Download PDFInfo
- Publication number
- WO2016159186A1 WO2016159186A1 PCT/JP2016/060563 JP2016060563W WO2016159186A1 WO 2016159186 A1 WO2016159186 A1 WO 2016159186A1 JP 2016060563 W JP2016060563 W JP 2016060563W WO 2016159186 A1 WO2016159186 A1 WO 2016159186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gel
- composition
- heparin
- weight
- external
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to a gel external composition containing a heparin-like substance. More specifically, the present invention relates to a gel-like composition for external use that has a heparin-like substance but has a reduced feeling of stickiness after application and has an excellent feeling of use.
- Heparin-like substances are polysulfated mucopolysaccharides such as chondroitin polysulfate, and are known to have moisturizing action, anti-inflammatory action, blood circulation promoting action, etc. and have few side effects, so they are widely used as active ingredients in externally used compositions. It is used.
- Patent Document 1 reports that a synergistic improvement in moisturizing effect is recognized by using a heparin-like substance and ceramide in combination.
- Patent Document 2 reports that the combined use of heparin-like substances and betaines provides an excellent therapeutic effect against rough skin associated with dry skin diseases and inflammatory skin diseases.
- Patent Document 3 reports that a combination of a heparin-like substance and a non-steroidal anti-inflammatory agent has an excellent therapeutic effect on dry skin diseases and inflammatory skin diseases. .
- the present inventor has made various studies on a preparation technique that uses a composition for external use containing a heparin-like substance as a gel, and the gel-like composition for external use containing a heparin-like substance causes stickiness after application to the affected area. I found a point. The problem of stickiness in such a gel-like external composition is accompanied by unpleasant sensation and lowering the feeling of use.
- an object of the present invention is to provide a gel-like composition for external use that has a helicin-like substance and is less sticky after coating and has an excellent feeling of use.
- the present inventor has intensively studied to solve the above-mentioned problems.
- a gel external composition containing a heparin-like substance and a gelling agent isopropanol is contained, and isopropanol is contained per 1 part by weight of the heparin-like substance.
- the present inventor has found that by satisfying the ratio of 77 to 180 parts by weight, stickiness after application can be suppressed and an excellent feeling of use can be provided.
- the present inventor has found that when the ratio of isopropanol to 82 to 180 parts by weight per 1 part by weight of the heparin-like substance is satisfied, drying after application becomes faster and the feeling of use is further improved. .
- the present inventor has also found that when isopropanol satisfies a ratio of 77 to 140 parts by weight per part by weight of the heparin-like substance, the gel-like external composition becomes transparent and exhibits excellent appearance properties. It was.
- the present inventor has shown that the gel-like external composition has a remarkably excellent granulation tissue formation inhibitory action, and is excellent in the prevention or treatment of hypertrophic scar and / or keloid. I found it.
- Item 1 A gel external composition comprising a heparin-like substance, isopropanol, and a gelling agent, and containing 77 to 180 parts by weight of isopropanol per 1 part by weight of the heparin-like substance.
- Item 2. Item 2. The gelled external composition according to Item 1, wherein the gelling agent is a carboxyvinyl polymer.
- Item 3. Item 3. The gel external composition according to Item 1 or 2, comprising isopropanol in a ratio of 82 to 140 parts by weight per 1 part by weight of the heparin-like substance.
- Item 4. Item 4.
- Item 5. The gel composition for external use according to any one of Items 1 to 4, which is used for moisture retention.
- Item 6. Item 5.
- Item 7. Item 5.
- Item 8. Item 5. The gel composition for external use according to any one of Items 1 to 4, which is used for improving the lump of the skin after scratches or burns, or the improvement of the firmness of the skin after scratches or burns.
- the stickiness after application is suppressed while containing a heparin-like substance, and an excellent feeling of use is provided.
- coating is quick and can also improve a usability
- mode of the gel-form external composition of this invention it is transparent and can also be equipped with the outstanding external appearance property.
- the gel-like composition for external use of the present invention has a remarkably excellent granulation tissue formation inhibitory effect, and skin diseases caused by excessive formation of granulation tissue such as skin swell, redness, tension, and lump. And skin symptoms can be effectively prevented or treated.
- the gel external composition of the present invention comprises a heparin-like substance, isopropanol, and a gelling agent, and contains isopropanol in a ratio of 77 to 180 parts by weight per 1 part by weight of the heparin-like substance.
- the gel-like external composition of the present invention will be described in detail.
- Heparin analog The gel external composition of the present invention contains a heparin-like substance as an active ingredient.
- Heparin-like substances are polysulfated mucopolysaccharides such as chondroitin polysulfate and are known drugs known to have moisturizing action, anti-inflammatory action, blood circulation promoting action, and the like.
- the origin of the heparin-like substance used in the present invention is not particularly limited. For example, it is obtained by polysulfating mucopolysaccharides, tissues of edible animals (for example, tracheal cartilage such as cattle and pigs) And the like extracted from the lung including In the gel composition for external use of the present invention, as the heparin-like substance, a heparin-like substance that is included in the Japanese Pharmacopoeia pharmaceutical standards is suitably used.
- the content of the heparin-like substance in the gel external composition of the present invention may be appropriately set according to the formulation form, etc., for example, 0.01 to 5% by weight, preferably 0.05 to 3% by weight. More preferred is 0.1 to 1% by weight.
- the gel external composition of the present invention contains isopropanol at a ratio of 77 to 180 parts by weight per 1 part by weight of the heparin-like substance.
- isopropanol at such a specific ratio, it becomes possible to suppress stickiness after coating and to provide an excellent feeling of use. Further, by including isopropanol at such a specific ratio, it is possible to exert a markedly excellent granulation tissue formation inhibitory action.
- the gel-like composition for external use of the present invention it is sufficient that isopropanol satisfies the above-mentioned ratio.
- isopropanol satisfies the ratio of 82 to 180 parts by weight per part by weight of the heparin-like substance, It is possible to suppress stickiness more effectively, further speed up drying after application, and further improve the feeling of use.
- isopropanol satisfies a ratio of 77 to 140 parts by weight per part by weight of the heparin-like substance, the gel-like external composition of the present invention becomes transparent and can be provided with excellent appearance properties.
- the content of isopropanol in the gel composition for external use of the present invention may be appropriately set within the range satisfying the ratio to the above-mentioned heparin analog, and is, for example, 7.7 to 60% by weight, preferably 10 to 50%. % By weight, more preferably 23 to 50% by weight.
- Gelling agent The gel-like external composition of the present invention contains a gelling agent in order to exhibit a gel-like form as a gelling agent.
- the gelling agent used in the present invention is not particularly limited as long as it is pharmaceutically acceptable.
- carboxyvinyl polymer, alkyl-modified carboxyvinyl polymer, polyacrylic acid, acrylic acid / alkyl methacrylate Copolymers, carboxymethyl cellulose, carrageenan, alginic acid, sodium alginate and the like can be mentioned.
- These gelling agents may be used individually by 1 type, and may be used in combination of 2 or more type.
- a carboxyvinyl polymer is preferably used from the viewpoint of effectively exhibiting an effect of suppressing stickiness after coating.
- the carboxyvinyl polymer is suitable for speeding up drying after application and providing transparency.
- the carboxyvinyl polymer is an acrylic acid-based hydrophilic cross-linked polymer.
- the molecular weight of the carboxyvinyl polymer used in the present invention is not particularly limited as long as it can be gelled.
- the viscosity (20 ° C.) in a 0.2 wt% aqueous solution is 10,000 to 40000 mPa ⁇ s, preferably 18000 to 35000 mPa ⁇ s.
- the viscosity (20 ° C.) of the 0.2 wt% aqueous solution was measured under the condition of pH 7.25 using a Brookfield type rotational viscometer (rotor No. 6 was used, rotation speed at measurement was 20 rpm). It is the value.
- the content of the gelling agent in the gelled external composition of the present invention may be in a range that can exhibit a gel state that can be used as a gelling agent, and may be appropriately set according to the type of gelling agent to be used. For example, it may be 0.01 to 5% by weight, preferably 0.1 to 3% by weight.
- the content of the carboxyvinyl polymer in the gel external composition of the present invention is usually 0.05 to 2% by weight, preferably 0.2 to 1%. % By weight, more preferably 0.4 to 0.8% by weight.
- the gel composition for external use of the present invention contains water in order to be gelled by the gelling agent.
- the content of water in the gel-like external composition of the present invention may be appropriately set according to the type of gelling agent used and the like, for example, 5 to 92.28% by weight, preferably 20 to 90% by weight. More preferred is 30 to 80% by weight.
- the gel composition for external use of the present invention may contain other pharmacological components as necessary in addition to the components described above.
- pharmacological components include antihistamines (eg, chlorpheniramine maleate), local anesthetics (dibucaine, methyl aminobenzoate, procaine, tetracaine, bupipacaine, mepipacaine, chloroprocaine, proparacaine, meprilucaine or salts thereof.
- the gel-form external composition of this invention may contain the other base and additive other than the said component as needed.
- bases and additives include aqueous bases such as lower alcohols other than isopropanol (such as ethanol) and polyhydric alcohols (such as glycerin, propylene glycol, dipropylene glycol, and 1,3-butylene glycol); (Olive oil, safflower oil, camellia oil, corn oil, rapeseed oil, sunflower oil, cottonseed oil, peanut oil, lard, squalane, fish oil, etc.), mineral oil (liquid paraffin, paraffin, gelled hydrocarbon, petrolatum, etc.), wax Waxes (beeswax, carnauba wax, candelilla wax, ceresin, rice wax, microcrystalline wax, etc.), ester oil (isopropyl myristate, isopropyl adipate, diethyl sebacate, isopropyl sebacate, isopropyl a
- Phosphoric acid / phosphate POE cetyl ether sodium phosphate, etc.
- POE (20-60 mol) sorbitan monooleate POE (10-60 mol) sorbitan monoisostearate, POE (10-80 mol) glyceryl mono Isostearate, POE (10-30 mol) grease Seryl monostearate, POE (20 to 100 mol) / polyoxypropylene modified silicone, POE / alkyl modified silicone, polyethylene glycol monolaurate, polyethylene glycol monopalmitate, polyethylene glycol monostearate, polyethylene glycol dilaurate, dipalmitate Polyethylene glycol, polyethylene glycol distearate, polyethylene glycol dioleate, polyethylene glycol diricinoleate, polyoxyethylene hydrogenated castor oil (5 to 100), polysorbate (20 to 85), glycerin fatty acid ester (such as glyceryl monostearate), hydrogen Surfactants such as added soybean phospholipid and hydrogenated lanolin
- the formulation form of the gel external composition of the present invention is not particularly limited as long as it is applied transdermally, and may be any of external medicines, cosmetics, skin cleansing agents, etc. Preferably, an external medicine is used.
- the gel composition for external use of the present invention can exhibit moisturizing action, anti-inflammatory action, blood circulation promoting action, etc. based on the heparin-like substance contained therein, so moisturizing, prevention or treatment of dry skin disease, inflammatory skin disease It is preferably used for the purpose of prevention or treatment.
- the gel-like external composition of the present invention should be used for the purpose of improving skin discoloration (redness, dullness), pulling (tension), lump, elasticity reduction, etc. after a wound or burn. Can do.
- the gel composition for external use of the present invention comprises keratosis of elbows, knees, heels, and ankles, fingers, limbs and cracks, dry skin, dry skin of children, moistness, bruises and sprains It can also be used for the purpose of improving later swelling, muscle pain, joint pain and the like.
- the gel-like external composition of the present invention has an excellent granulation-inhibiting action, and therefore skin diseases such as hypertrophic scars, keloids, skin swell after burns / burns, redness, tension, lumps and other skin diseases and skin symptoms It can be suitably used for the purpose of prevention or treatment.
- Test Example 1 Production and evaluation of composition for external use External compositions having the compositions shown in Tables 2 to 4 were prepared. The feeling of use (stickiness, dripping, ease of drying), appearance, and properties of each composition for external use was evaluated according to the following criteria.
- compositions for external use were confirmed visually and touched to determine whether they exhibited a gel that could be used as a gel or a liquid.
- a gel-like external composition containing a heparin-like substance when isopropanol is contained in a ratio of more than 180 parts by weight per 1 part by weight of the heparin-like substance, the gel-like composition cannot be exhibited and dripping at the time of application is recognized. In addition, cloudiness of the preparation was confirmed.
- Test Example 2 Evaluation of granulation tissue formation inhibitory effect
- a sterilized cotton pellet ("Richmond Cotton Pellet", manufactured by Agusa Japan Co., Ltd.) prepared by adding a small incision on the midline of the back of a 7-week-old (including acclimatization period of 1 week) Slc: Wistar rat. After one was inserted, the incision was sutured.
- Six hours after the stitching about 1 g of the gel-like external composition shown in Table 5 was applied (initial application) on the skin of the cotton pellet implantation site.
- About 1 g of the gel external composition shown in Table 5 was applied to the cotton pellet implantation site once a day for a total of 6 days at an interval of 24 hours from the initial application.
- the granulation formed around the cotton pellet was extracted from the back of the rat together with the cotton pellet. After the extracted granulation was dried, the weight was measured, and this was defined as the granulation dry weight. Further, as a control, the dry weight of granulation was determined in the same manner as described above except that the gel-like external composition was not applied. The value obtained by subtracting the weight of the embedded cotton pellets from the dry weight of the granulation was taken as the granulation weight. In this test, the average granulation weight was calculated using 10 rats per group. Moreover, granulation formation suppression rate (%) was computed from the obtained granulation weight according to the following formula
- Table 5 shows granulation formation inhibition rates recognized by application of each gel-like composition for external use. From this result, in the case of isopropanol alone (Comparative Example 15), there was no granulation formation inhibitory effect, and in the case of the heparin-like substance alone (Comparative Example 2), the granulation formation inhibition rate was only 4.6%. When isopropanol was used in a ratio of 77 to 180 parts by weight per part by weight (Example 2), the granulation formation inhibition rate was 8.6%, and the granulation formation inhibition effect was 1.8% compared to Comparative Example 2. It was improved to more than double.
- Formulation example A gel-like external composition having the composition shown in Table 6 was prepared. When these gel-like external compositions were evaluated for stickiness after application under the same conditions as in Test Example 1, it was confirmed that stickiness was suppressed. Further, the gel-like external compositions of Formulation Examples 2, 4, 5, and 7 to 9 had a transparent appearance property.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
L'objet de la présente invention est de fournir une composition de type gel pour application externe, qui présente une adhésivité réduite après son application sur la peau et présente par conséquent une excellente sensation pendant l'application en dépit du fait que la composition contient une substance similaire à l'héparine. La solution selon l'invention porte sur une composition de type gel pour application externe, qui comprend une substance similaire à l'héparine et un agent gélifiant. Dans la composition, de l'isopropanol est ajouté, et la condition selon laquelle la quantité d'isopropanol est de 77 à 180 parties en poids par rapport à 1 partie en poids de la substance semblable à l'héparine est satisfaite. De cette manière, l'adhésivité de la composition après son application peut être réduite et une excellente sensation pendant l'application peut être conférée à la composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-074068 | 2015-03-31 | ||
JP2015074068A JP6628488B2 (ja) | 2015-03-31 | 2015-03-31 | ゲル状外用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016159186A1 true WO2016159186A1 (fr) | 2016-10-06 |
Family
ID=57006943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/060563 WO2016159186A1 (fr) | 2015-03-31 | 2016-03-30 | Composition de type gel pour application externe |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6628488B2 (fr) |
WO (1) | WO2016159186A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020004194A1 (fr) * | 2018-06-28 | 2020-01-02 | 小林製薬株式会社 | Composition à usage externe |
WO2020004193A1 (fr) * | 2018-06-28 | 2020-01-02 | 小林製薬株式会社 | Composition à usage externe |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7214331B2 (ja) * | 2016-12-28 | 2023-01-30 | 小林製薬株式会社 | 医薬組成物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012092067A (ja) * | 2010-10-28 | 2012-05-17 | Kowa Co | 非ステロイド性消炎鎮痛外用剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05117141A (ja) * | 1991-10-25 | 1993-05-14 | Toko Yakuhin Kogyo Kk | 副腎エキス含有消炎鎮痛ゲル剤 |
-
2015
- 2015-03-31 JP JP2015074068A patent/JP6628488B2/ja active Active
-
2016
- 2016-03-30 WO PCT/JP2016/060563 patent/WO2016159186A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012092067A (ja) * | 2010-10-28 | 2012-05-17 | Kowa Co | 非ステロイド性消炎鎮痛外用剤 |
Non-Patent Citations (3)
Title |
---|
HEPARIN RUIJI BUSSHITSU GEL 0.3% 'AMEL' TENPU BUNSHO, 2013, pages 1 - 2 * |
HIRUDOID (REGISTERED TRADEMARK) GEL 0.3% TENPU BUNSHO, 2008 * |
HOSOIDON (REGISTERED TRADEMARK) GEL 0.3% TENPU BUNSHO, 2009, pages 1 - 2 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020004194A1 (fr) * | 2018-06-28 | 2020-01-02 | 小林製薬株式会社 | Composition à usage externe |
WO2020004193A1 (fr) * | 2018-06-28 | 2020-01-02 | 小林製薬株式会社 | Composition à usage externe |
Also Published As
Publication number | Publication date |
---|---|
JP6628488B2 (ja) | 2020-01-08 |
JP2016193854A (ja) | 2016-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5897164B2 (ja) | 外用組成物 | |
JP6666068B2 (ja) | 外用組成物 | |
JP4786630B2 (ja) | 皮膚外用剤 | |
WO2016159186A1 (fr) | Composition de type gel pour application externe | |
JP2005060234A (ja) | 皮膚外用剤 | |
JP6725207B2 (ja) | 皮膚色素沈着抑制剤 | |
JP7313111B2 (ja) | 皮脂分泌促進剤及び外用組成物 | |
JP2012092067A (ja) | 非ステロイド性消炎鎮痛外用剤 | |
JP2005060233A (ja) | 皮膚外用剤 | |
JP7446711B2 (ja) | 皮膚外用組成物 | |
JP6851139B2 (ja) | 外用組成物 | |
JP7329910B2 (ja) | 皮膚外用組成物 | |
JP7299682B2 (ja) | 皮膚外用組成物 | |
JP7299683B2 (ja) | 皮膚外用組成物 | |
JP7025129B2 (ja) | 筋痙攣治療剤 | |
JP7282476B2 (ja) | 外用組成物 | |
JP6735587B2 (ja) | 外用組成物 | |
JP2017088541A (ja) | 異常瘢痕形成抑制剤 | |
JP7153429B2 (ja) | 活性酸素消去剤 | |
JP2023120388A (ja) | 外用組成物 | |
JP2019006697A (ja) | 活性酸素消去剤 | |
JP7092498B2 (ja) | 尿かぶれ改善剤 | |
WO2015151991A1 (fr) | Composition pharmaceutique pour usage externe | |
JP2024095558A (ja) | 皮膚外用剤組成物 | |
JP2018203673A (ja) | 皮脂分泌促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16773067 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16773067 Country of ref document: EP Kind code of ref document: A1 |